Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

972
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
972
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

43
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
43
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

166
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
166
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

42
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
42
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis.

The Annals of pharmacotherapy·2026
Same author

PharmDs on call: Responding to the needs of careers, family, and life.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Exploring Pharmacists' Perceptions of Text-Based Artificial Intelligence in Resident and Student Education.

Hospital pharmacy·2024
Same author

A Resident-Preceptor Collaboration to Encourage Wellness and Reduce Burnout Amongst Pharmacy Residents.

American journal of pharmaceutical education·2023
Same author

Risk Stratification for Supratherapeutic Peak Anti-Xa Levels in Adult Patients on Therapeutic Enoxaparin.

The Annals of pharmacotherapy·2023
Same author

Impact of concomitant fluconazole on direct oral anticoagulant bleeding risk.

Pharmacotherapy·2022

Related Experiment Video

Updated: Oct 2, 2025

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

811

Anticoagulation Considerations in Liver Disease.

Andrew C Stone1, Joshua W Gaborcik, Megan E Smetana

  • 1Department of Pharmacy, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, Columbus (Dr Stone); and Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus (Drs Gaborcik and Smetana).

Critical Care Nursing Quarterly
|February 25, 2022
PubMed
Summary

Liver disease causes complex coagulopathy, impacting bleeding and thrombosis risks. Standard labs may not fully reflect these dangers, necessitating careful anticoagulant selection for cirrhosis patients.

More Related Videos

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

8.9K
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

16.6K

Related Experiment Videos

Last Updated: Oct 2, 2025

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

811
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

8.9K
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

16.6K

Area of Science:

  • Hepatology
  • Hematology
  • Critical Care Medicine

Background:

  • Coagulopathy is a common complication in liver disease, increasing risks of both bleeding and thrombosis.
  • Standard laboratory tests may not accurately predict the actual hemostatic risks in patients with cirrhosis.
  • Managing venous thromboembolism in cirrhosis requires careful consideration of anticoagulant therapy.

Purpose of the Study:

  • To elucidate the complexities of coagulopathy in liver disease.
  • To explain how liver disease affects routine laboratory coagulation values.
  • To guide critical care nurses on anticoagulant therapy for cirrhotic patients.

Main Methods:

  • Literature review of coagulopathy in liver disease.
  • Analysis of laboratory value interpretation in cirrhosis.
  • Discussion of anticoagulant drug selection and monitoring strategies.

Main Results:

  • Coagulopathy in liver disease presents a paradox of bleeding and thrombotic risks.
  • Laboratory values like PT/INR and PTT may not correlate with clinical thrombotic or bleeding events.
  • Anticoagulant therapy in cirrhosis demands individualized assessment and vigilant monitoring.

Conclusions:

  • Understanding the nuances of liver disease coagulopathy is crucial for accurate risk assessment.
  • Relying solely on traditional lab values can be misleading in managing cirrhotic patients.
  • Careful patient evaluation and tailored anticoagulant strategies are essential for safe and effective treatment.